| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/10/2023 | 77.66% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 07/13/2022 | 77.66% | Ladenburg Thalmann | → $21 | Initiates Coverage On | → Buy |
| 05/10/2022 | 77.66% | HC Wainwright & Co. | $14 → $21 | Maintains | Buy |
| 03/02/2022 | 18.44% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
What is the target price for Nuvectis Pharma (NVCT)?
The latest price target for Nuvectis Pharma (NASDAQ: NVCT) was reported by HC Wainwright & Co. on February 10, 2023. The analyst firm set a price target for $21.00 expecting NVCT to rise to within 12 months (a possible 77.66% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nuvectis Pharma (NVCT)?
The latest analyst rating for Nuvectis Pharma (NASDAQ: NVCT) was provided by HC Wainwright & Co., and Nuvectis Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Nuvectis Pharma (NVCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvectis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvectis Pharma was filed on February 10, 2023 so you should expect the next rating to be made available sometime around February 10, 2024.
Is the Analyst Rating Nuvectis Pharma (NVCT) correct?
While ratings are subjective and will change, the latest Nuvectis Pharma (NVCT) rating was a reiterated with a price target of $0.00 to $21.00. The current price Nuvectis Pharma (NVCT) is trading at is $11.82, which is within the analyst's predicted range.